Skip to main content
An official website of the United States government

Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial

Trial Status: active

This phase II trial tests how well glofitamab, polatuzumab vedotin, and obinutuzumab in combination with standard chemotherapy treatment, rituximab, cyclophosphamide, doxorubicin, and prednisone, works in treating patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or transformed lymphoma. This clinical trial also evaluates how well adding glofitamab, polatuzumab vedotin, and obinutuzumab early to treatment with rituximab, cyclophosphamide, doxorubicin and prednisone works in reducing the amount of chemotherapy needed to treat these types of lymphoma. Glofitamab is a bispecific monoclonal antibody that can bind to two different proteins at the same time. Glofitamab binds to a protein CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells and may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called monomethylauristatin E (MMAE). Polatuzumab vedotin is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79B receptors, and delivers MMAE to kill them. Obinutuzumab and rituximab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Chemotherapy often causes many short- and long-term side effects, especially in people over 65 years of age with other medical problems. Lowering the dose of chemotherapy may cause fewer and more mild side effects than standard doses. Giving glofitamab, polatuzumab vedotin, and obinutuzumab early in the treatment plan with rituximab, cyclophosphamide, doxorubicin and prednisone may kill more cancer cells and reduce the amount of chemotherapy needed to treat patients with DLBCL, HGBCL or transformed lymphoma.